He provided balanced points to the bull and bear case, however there isn't a whole lot of bear case points, so most articles will seem "pumped." Maybe beaverlicker should write a Seeking Alpha article.
drcas, welcome aboard. There is a doctor posting somewhere on this board (he must be in surgery now). We make a fine mix to provide well-balanced review for NOOBS (some might wonder about the giddyness and dry humor, but they should know that we know that this is likely going to appreciate significantly, it is just a matter of when). We have a doctor, a truckdriver (maybe), an IT specialist, a cat (me), and a busy beaver w/ brandon.
I found the artical to be very informative and matching much of the DD that I and Brandon had done in the past. The comparison with the PFE drug is pretty much spot on with regard to potency, resistance, advantages, etc. There is great interest in this company and the new trial data we are waiting for should confirm. The share price targets may have given it a pumper slant. I think we see double easy and possibly around $20 at some point. A buyout could change it all of course. :#3
Do you have any thoughts on the timing ie 6 mths 1 year . Ive heard that the second trial results may be released in March . This may be the catalyst to start an up tic for the share price . But long term the company is not acquired i keep thinking about the effective life of these newer drugs . Drug resistances seem to be developing much faster . It does take time to get on hospital approved formulary ,